Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 Ballot 3 World

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

EvidenceVariable: PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)

Official URL: https://fevir.net/resources/EvidenceVariable/267231 Version: 1.0.0-ballot3
Standards status: Informative Computable Name: PK_Change_From_Baseline_in_Tmax_of_Glucagon_Nasal_Powder_and_Glucagon_Hydrochloride_IM_NCT03421379
Other Identifiers: FEvIR Object Identifier: FEvIR Object Identifier#267231, FEvIR Linking Identifier: NCT03421379-secondaryOutcome-4, OID:2.16.840.1.113883.4.642.40.44.24.175

Copyright/Legal: Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse).

PK assessment measured the change from baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM.

version: 14; Last updated: 2026-09-02 17:15:21+0000

Profile: VariableDefinition

ArtifactPublicationStatus: Active

url: EvidenceVariable PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)

identifier: FEvIR Object Identifier/267231, FEvIR Linking Identifier/NCT03421379-secondaryOutcome-4, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.24.175

version: 1.0.0-ballot3

name: PK_Change_From_Baseline_in_Tmax_of_Glucagon_Nasal_Powder_and_Glucagon_Hydrochloride_IM_NCT03421379

title: PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)

citeAs:

PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267231. Revised 2026-09-02. Available at: https://fevir.net/resources/EvidenceVariable/267231. Computable resource at: https://fevir.net/resources/EvidenceVariable/267231#json.

status: Active

date: 2026-11-05 14:34:28+0000

author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description:

PK assessment measured the change from baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM.

copyright:

Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse).

Definitions

-Concept
*PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM PK assessment measured the change from baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM.

handling: Evidence variable handling not specified

Timings

-Text
*Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration